Relationship between TIM-3 Immune Response Expression and Nasopharyngeal Carcinoma Histopathology
DOI:
10.29303/jbt.v26i1.11659Published:
2025-12-31Downloads
Abstract
Nasopharyngeal carcinoma is a malignancy of the nasopharyngeal epithelium that is often diagnosed at an advanced stage and is associated with impaired immune regulation in the tumor microenvironment. T-cell immunoglobulin and mucin domain-3 (TIM-3) is an immune checkpoint molecule that plays a role in suppressing the antitumor immune response. This study aims to analyze the relationship between TIM-3 immune response expression and the histopathological type of nasopharyngeal carcinoma. An analytical study with a cross-sectional design was conducted on 40 paraffin blocks of nasopharyngeal carcinoma patients at H. Adam Malik General Hospital, Medan, selected by consecutive sampling. TIM-3 expression was analyzed using real-time polymerase chain reaction (RT-PCR) with the calculation of ΔCT values against the control gene β-actin. Univariate analysis was used to describe the characteristics of the subjects, while bivariate analysis used the Kruskal–Wallis test to assess the relationship between TIM-3 expression and histopathological type. The majority of subjects were male (65%) with a mean age of 48.2 ± 11.1 years. The most common histopathological type was non-keratinizing squamous cell carcinoma (90%). The mean TIM-3 expression was 4.3 ± 1.6 with a median of 4.8 (−0.1–6.7), and 97.5% of samples showed increased expression. The Kruskal–Wallis test showed no significant correlation between TIM-3 expression and histopathological type (p = 0.452). It was concluded that TIM-3 expression is generally increased in nasopharyngeal carcinoma, but is not significantly associated with histopathological type. Further research is needed to evaluate the biological role and therapeutic potential of TIM-3 in this disease.
Keywords:
Histopatologi Immune checkpoint Karsinoma nasofaring TIM-3 RT-PCRReferences
Acharya, N., Sabatos-Peyton, C., & Anderson, A. C. (2020). Tim-3 finds its place in the cancer immunotherapy landscape. Journal for immunotherapy of cancer, 8(1), e000911. https://doi.org/10.1136/jitc-2020-000911
Alsafadi, N., Alqarni, M. S., Attar, M., Mgarry, R., & Bokhari, A. (2020). Nasopharyngeal Cancer: Prevalence, Outcome, and Impact on Health-Related Quality of Life at Princess Norah Oncology Center, Jeddah, Saudi Arabia. Cureus, 12(5), e8199. https://doi.org/10.7759/cureus.8199
American Joint Committee on Cancer. (2018). AJCC cancer staging manual (8th ed., Part 1, pp. 213–219)
Anderson, A.C., Joller, N., & Kuchroo, V.K. (2016). Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity, 44(5), 989–1004.
Chen, Y. P., Chan, A. T. C., Le, Q. T., Blanchard, P., Sun, Y., & Ma, J. (2019). Nasopharyngeal carcinoma. Lancet (London, England), 394(10192), 64–80. https://doi.org/10.1016/S0140-6736(19)30956-0
Dominguez AR, Cirauqui B, Castano AG, Cabellos RA, Maseda AC, Fernandez BC, Rey LI, Casadevall JR and Arrazubi V. (2021). SEOM-TTC clinical guidilines in nasopharynx cancer (2021). Clinical guidilines in oncology. Doi.org/10.1007/s12094-022-02814.
Ho, F. C., Tham, I. W., Earnest, A., Lee, K. M., & Lu, J. J. (2012). Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence. BMC cancer, 12, 98. https://doi.org/10.1186/1471-2407-12-98
Homayouni, V., Ganjalikhani-Hakemi, M., Rezaei, A., Khanahmad, H., Behdani, M., & Lomedasht, F. K. (2016). Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3). Iranian journal of basic medical sciences, 19(11), 1201–1208.
Liemiyah, R. et al. (2024) ‘Epidemiological Characteristics and 3-year Overall Survival Outcome of Nasopharyngeal Cancer in Central Java: A Single Institution Retrospective Study’, Indonesian Journal of Cancer, 18(2), pp. 143–155. Available at: https://doi.org/10.33371/ijoc.v18i2.1083.
Mountain, J. L., & Risch, N. (2014). Assessing genetic contributions to phenotypic differences among'racial'and'ethnic'groups. Nature genetics, 36(Suppl 11), S48-S53.
Salehiniya, H., Mohammadian, M., Mohammadian-Hafshejani, A., & Mahdavifar, N. (2018). Nasopharyngeal cancer in the world: epidemiology, incidence, mortality and risk factors. WCRJ, 5(1), e1046
Shah, A. B., & Nagalli, S. (2024). Nasopharyngeal Carcinoma. In StatPearls. StatPearls Publishing.
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
Tsao, S.W., Tsang, C.M., & Lo, K.W. (2014). Epstein–Barr virus infection and nasopharyngeal carcinoma. Philosophical Transactions of the Royal Society B, 369(1644), 20130570.
Van Velsen, J. S., van der Vegt, B., Plaat, B. E. C., Langendijk, J. A., Epskamp-Kuijpers, C. C. H. J., van Dijk, B. A. C., & Oosting, S. F. (2024). Nasopharyngeal carcinoma: nationwide trends in subtype-specific incidence and survival over 3 decades in a non-endemic area. Journal of cancer research and clinical oncology, 150(2), 49. https://doi.org/10.1007/s00432-023-05547-8
Wolf, Y., Anderson, A.C., & Kuchroo, V.K. (2020). TIM3 comes of age as an inhibitory receptor. Nature Reviews Immunology, 20(3), 173–185.
Wong, K. Y., Basri, H., Wong, Y. L., Wahab, M., Haji Kipli, N. P., Niap, I., & Ooi, C. H. (2023). Epidemiology of Nasopharyngeal Carcinoma in Sarawak, East Malaysia. Asian Pacific journal of cancer prevention : APJCP, 24(8), 2817–2822. https://doi.org/10.31557/APJCP.2023.24.8.2817
World Health Organization. (2017). WHO classification of head and neck tumours (4th ed.). Lyon: IARC Press.
Wu, J., Lin, G., Zhu, Y., (2017). Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status. Scientific Reports, 7, 8869. https://doi.org/10.1038/s41598-017-09484-8
Wu, M., Wu, A., Zhang, X., Li, Y., Li, B., Jin, S., Dong, Q., Niu, X., Zhang, L., Zhou, X., Du, J., Wu, Y., Zhai, W., Zhou, X., Qiu, L., Gao, Y., & Zhao, W. (2023). Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy. Biochemical pharmacology, 212, 115583. https://doi.org/10.1016/j.bcp.2023.115583
Xiao, Y., Qing, J., Li, B., Chen, L., Nong, S., Yang, W., Tang, X., & Chen, Z. (2020). TIM-3 Participates in the Invasion and Metastasis of Nasopharyngeal Carcinoma via SMAD7/SMAD2/SNAIL1 Axis-Mediated Epithelial-Mesenchymal Transition. OncoTargets and therapy, 13, 1993–2006. https://doi.org/10.2147/OTT.S237222
Xie, X., Feng, Y., Fan, P., Dong, D., Yao, X., Peng, Y., & Wang, R. (2023). Increased co-expression of TIM-3 with TIGIT or 2B4 on CD8+ T cells is aassociated with poor prognosis in locally advanced nasopharyngeal carcinoma. Biomolecules & biomedicine, 23(4), 584–595. https://doi.org/10.17305/bb.2022.8562
Xu, J. Y., Wei, X. L., Wang, Y. Q., & Wang, F. H. (2022). Current status and advances of immunotherapy in nasopharyngeal carcinoma. Therapeutic advances in medical oncology, 14, 17588359221096214. https://doi.org/10.1177/17588359221096214
Yang, F., Zeng, Z., Li, J., Ren, X., & Wei, F. (2021). TIM-3 and CEACAM1 are Prognostic Factors in Head and Neck Squamous Cell Carcinoma. Frontiers in molecular biosciences, 8, 619765. https://doi.org/10.3389/fmolb.2021.619765
Yu, H., Yin, X., Mao, Y., Chen, M., Tang, Q., & Yan, S. (2022). The global burden of nasopharyngeal carcinoma from 2009 to 2019: an observational study based on the Global Burden of Disease Study 2019. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 279(3), 1519–1533. https://doi.org/10.1007/s00405-021-06922-2
Zhang, Y., Rumgay, H., Li, M., Cao, S., & Chen, W. (2023). Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling. JMIR public health and surveillance, 9, e49968. https://doi.org/10.2196/49968
License
Copyright (c) 2026 Vina Andita Harahap, Farhat Farhat, Siti Nursiah, Ashri Yudhistira, Ramlan Sitompul, Juliandi Harahap
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.
